This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path
by Zacks Equity Research
Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.
Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment
by Zacks Equity Research
Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.
Gilead Up on Positive Final Results for Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.
Lilly Seeks Emergency Use of Coronavirus Antibody Candidate
by Kinjel Shah
Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.
Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.
Vir Biotechnology (VIR) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Vir Biotechnology (VIR) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
Regeneron's Coronavirus Antibody Cocktail Study Data Promising
by Zacks Equity Research
Regeneron (REGN) announces encouraging initial data from its seamless phase I/II/III study, evaluating antibody cocktail candidate, REGN-COV2, in non-hospitalized patients with COVID-19.
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib
by Zacks Equity Research
The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody
by Zacks Equity Research
Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.
Lilly's Coronavirus Antibody Shows Positive Effect in Phase II
by Zacks Equity Research
Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate.
Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study
by Zacks Equity Research
Eli Lilly (LLY) releases positive initial data from a phase III study evaluating Olumiant (baricitinib) in combination with Gilead's remdesivir for hospitalized patients with COVID-19.
Glaxo/Vir Biotech Begin Clinical Study on Coronavirus Therapy
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology have a collaboration to develop antibody therapies for treating COVID-19.
Market Waits for Major Economic Data This Week
by Zacks Equity Research
Market Waits for Major Economic Data This Week.
Big Week of Econ Data Starts on a Lull
by Mark Vickery
Although this will be a big week for economic data, today sees nothing new on this front.
Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH
by Kinjel Shah
Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance
by Zacks Equity Research
Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.
Glaxo Signs Another Deal to Develop a Coronavirus Vaccine
by Zacks Equity Research
Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.
Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.
Lilly Begins Phase III Study on Olumiant for Coronavirus
by Zacks Equity Research
Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.
Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I
by Zacks Equity Research
Lilly (LLY) is set to study JS016 as a monotherapy and in combination with antibody treatments including LY-CoV555, its first potential COVID-19 antibody candidate that recently entered phase I.
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
Glaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant
by Zacks Equity Research
Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.